U.K. Cost Of EPO Per Quality Adjusted Life Year Drops Over 10-Fold Since '90
The U.K. cost of epoetin alfa treatment per quality adjusted life year (QALY) dropped from a high of more than $200,000 (L126,290) in 1990 to an estimated range of $5,000 to $15,000 in 1997, according to a report published Sept. 15 by the Association of the British Pharmaceutical Industry.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth